|
|
Volumn 8, Issue 6, 2009, Pages 439-440
|
|
Tapping into combination pills for HIV
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE;
ANTIRETROVIRUS AGENT;
ATAZANAVIR;
CHEMOKINE RECEPTOR CCR5 ANTAGONIST;
DARUNAVIR;
EFAVIRENZ;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ELVITEGRAVIR;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
GS 9350;
LAMIVUDINE PLUS ZIDOVUDINE;
LOPINAVIR PLUS RITONAVIR;
PF 3716539;
PROTEINASE INHIBITOR;
RALTEGRAVIR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SPI 452;
UNCLASSIFIED DRUG;
ARTICLE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG BLOOD LEVEL;
DRUG CONTRAINDICATION;
DRUG COST;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MARKETING;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG TOLERABILITY;
GASTROINTESTINAL TOXICITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LOW DRUG DOSE;
NEUROTOXICITY;
PREGNANCY;
PRIORITY JOURNAL;
SIDE EFFECT;
VIROTHERAPY;
ADENINE;
ANTI-RETROVIRAL AGENTS;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
DRUG INDUSTRY;
HIV INFECTIONS;
HUMANS;
ORGANOPHOSPHORUS COMPOUNDS;
OXAZINES;
PHOSPHONIC ACIDS;
|
|
EID: 66749114263
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2917 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|